COVID-19: How Orbis International is managing operations

Article

Danny Haddad, MD, chief of program at Orbis International, shares an update on how the company's operations have shifted during the coronavirus pandemic, as well as the record-breaking impact on one of its telehealth platforms.
 


See more coronavirus coverage here

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Related Content
From Optical to Digital Precision: Advancing Retinal Surgery with the ARTEVO 850 Microscope

From Optical to Digital Precision: Advancing Retinal Surgery with the ARTEVO 850 Microscope

Rodolfo Mastropasqua MD, PhD, FEBO
August 19th 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

August 19th 2025
Podcast
A baby is hugged by their parent in a doctor's office during an exam. Concept image for retinoblastoma diagnosis and treatment, importance of early intervention in paediatric ocular disease. Image credit: ©phoderstock – stock.adobe.com

Patient outcomes in retinoblastoma impacted by parents' interventional delays

Lynda Charters
August 19th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

August 19th 2025
Podcast
Tyson J. Brunstetter, MBA, OD, PhD, FAAO, FAsMA presents a keynote on spaceflight-associated neuro-ocular syndrome (SANS). (All images courtesy of Heidelberg Engineering)

Recap: The future of imaging is out of this world

Hattie Hayes
August 19th 2025
Article
A glass building with a sign reading "RESERVE BANK." There are $100 Australian bank notes superimposed over the image. Concept image for Mirugen funding, cell reprogramming biologic biotech business of retina care news. Image credit: ©Rose Makin – stock.adobe.com

Australian biotech firm Mirugen secures major funding for cell reprogramming therapy

Hattie Hayes
August 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.